Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 74

1.

EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer.

Tulchinsky E, Demidov O, Kriajevska M, Barlev NA, Imyanitov E.

Biochim Biophys Acta Rev Cancer. 2018 Nov 9. pii: S0304-419X(18)30142-2. doi: 10.1016/j.bbcan.2018.10.003. [Epub ahead of print] Review.

PMID:
30419315
2.

The biological basis and clinical symptoms of CAR-T therapy-associated toxicites.

Titov A, Petukhov A, Staliarova A, Motorin D, Bulatov E, Shuvalov O, Soond SM, Piacentini M, Melino G, Zaritskey A, Barlev NA.

Cell Death Dis. 2018 Sep 4;9(9):897. doi: 10.1038/s41419-018-0918-x.

3.

Effects of mycoplasma infection on the host organism response via p53/NF-κB signaling.

Borchsenius SN, Daks A, Fedorova O, Chernova O, Barlev NA.

J Cell Physiol. 2018 Jan;234(1):171-180. doi: 10.1002/jcp.26781. Epub 2018 Aug 26.

PMID:
30146800
4.

Novel isatin-derived molecules activate p53 via interference with Mdm2 to promote apoptosis.

Fedorova O, Daks A, Petrova V, Petukhov A, Lezina L, Shuvalov O, Davidovich P, Kriger D, Lomert E, Tentler D, Kartsev V, Uyanik B, Tribulovich V, Demidov O, Melino G, Barlev NA.

Cell Cycle. 2018;17(15):1917-1930. doi: 10.1080/15384101.2018.1506664. Epub 2018 Sep 5.

PMID:
30109812
5.

Combined treatment of human multiple myeloma cells with bortezomib and doxorubicin alters the interactome of 20S proteasomes.

Mittenberg AG, Kuzyk VO, Shabelnikov SV, Gorbach DP, Shatrova AN, Fedorova OA, Barlev NA.

Cell Cycle. 2018;17(14):1745-1756. doi: 10.1080/15384101.2018.1496742. Epub 2018 Aug 1.

PMID:
30009671
6.

Specific Drug Delivery to Cancer Cells with Double-Imprinted Nanoparticles against Epidermal Growth Factor Receptor.

Canfarotta F, Lezina L, Guerreiro A, Czulak J, Petukhov A, Daks A, Smolinska-Kempisty K, Poma A, Piletsky S, Barlev NA.

Nano Lett. 2018 Aug 8;18(8):4641-4646. doi: 10.1021/acs.nanolett.7b03206. Epub 2018 Jul 9.

PMID:
29969563
7.

Ca2+ -depended signaling pathways regulate self-renewal and pluripotency of stem cells.

Ermakov A, Daks A, Fedorova O, Shuvalov O, Barlev NA.

Cell Biol Int. 2018 May 31. doi: 10.1002/cbin.10998. [Epub ahead of print] Review.

PMID:
29851182
8.

TG2 regulates the heat-shock response by the post-translational modification of HSF1.

Rossin F, Villella VR, D'Eletto M, Farrace MG, Esposito S, Ferrari E, Monzani R, Occhigrossi L, Pagliarini V, Sette C, Cozza G, Barlev NA, Falasca L, Fimia GM, Kroemer G, Raia V, Maiuri L, Piacentini M.

EMBO Rep. 2018 Jul;19(7). pii: e45067. doi: 10.15252/embr.201745067. Epub 2018 May 11.

PMID:
29752334
9.

Non-alcoholic fatty liver disease severity is modulated by transglutaminase type 2.

Piacentini M, Baiocchini A, Del Nonno F, Melino G, Barlev NA, Rossin F, D'Eletto M, Falasca L.

Cell Death Dis. 2018 Feb 15;9(3):257. doi: 10.1038/s41419-018-0292-8.

10.

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.

Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M, Candi E, Carmona-Gutierrez D, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Cohen GM, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D'Angiolella V, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, DeBerardinis RJ, Deshmukh M, Di Daniele N, Di Virgilio F, Dixit VM, Dixon SJ, Duckett CS, Dynlacht BD, El-Deiry WS, Elrod JW, Fimia GM, Fulda S, García-Sáez AJ, Garg AD, Garrido C, Gavathiotis E, Golstein P, Gottlieb E, Green DR, Greene LA, Gronemeyer H, Gross A, Hajnoczky G, Hardwick JM, Harris IS, Hengartner MO, Hetz C, Ichijo H, Jäättelä M, Joseph B, Jost PJ, Juin PP, Kaiser WJ, Karin M, Kaufmann T, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Knight RA, Kumar S, Lee SW, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lowe SW, Luedde T, Lugli E, MacFarlane M, Madeo F, Malewicz M, Malorni W, Manic G, Marine JC, Martin SJ, Martinou JC, Medema JP, Mehlen P, Meier P, Melino S, Miao EA, Molkentin JD, Moll UM, Muñoz-Pinedo C, Nagata S, Nuñez G, Oberst A, Oren M, Overholtzer M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pereira DM, Pervaiz S, Peter ME, Piacentini M, Pinton P, Prehn JHM, Puthalakath H, Rabinovich GA, Rehm M, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Ryan KM, Sayan E, Scorrano L, Shao F, Shi Y, Silke J, Simon HU, Sistigu A, Stockwell BR, Strasser A, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Thorburn A, Tsujimoto Y, Turk B, Vanden Berghe T, Vandenabeele P, Vander Heiden MG, Villunger A, Virgin HW, Vousden KH, Vucic D, Wagner EF, Walczak H, Wallach D, Wang Y, Wells JA, Wood W, Yuan J, Zakeri Z, Zhivotovsky B, Zitvogel L, Melino G, Kroemer G.

Cell Death Differ. 2018 Mar;25(3):486-541. doi: 10.1038/s41418-017-0012-4. Epub 2018 Jan 23. Review.

11.

BTK blocks the inhibitory effects of MDM2 on p53 activity.

Rada M, Althubiti M, Ekpenyong-Akiba AE, Lee KG, Lam KP, Fedorova O, Barlev NA, Macip S.

Oncotarget. 2017 Nov 20;8(63):106639-106647. doi: 10.18632/oncotarget.22543. eCollection 2017 Dec 5.

12.

Co-expression of RelA/p65 and ACTN4 induces apoptosis in non-small lung carcinoma cells.

Lomert E, Turoverova L, Kriger D, Aksenov ND, Nikotina AD, Petukhov A, Mittenberg AG, Panyushev NV, Khotin M, Volkov K, Barlev NA, Tentler D.

Cell Cycle. 2018;17(5):616-626. doi: 10.1080/15384101.2017.1417709. Epub 2018 Jan 22.

PMID:
29251177
13.

Proapoptotic modification of substituted isoindolinones as MDM2-p53 inhibitors.

Grigoreva TA, Novikova DS, Petukhov AV, Gureev MA, Garabadzhiu AV, Melino G, Barlev NA, Tribulovich VG.

Bioorg Med Chem Lett. 2017 Dec 1;27(23):5197-5202. doi: 10.1016/j.bmcl.2017.10.049. Epub 2017 Oct 20.

PMID:
29089230
14.

E3 ubiquitin ligase Pirh2 enhances tumorigenic properties of human non-small cell lung carcinoma cells.

Daks A, Petukhov A, Fedorova O, Shuvalov O, Merkulov V, Vasileva E, Antonov A, Barlev NA.

Genes Cancer. 2016 Nov;7(11-12):383-393. doi: 10.18632/genesandcancer.123.

15.

One-carbon metabolism and nucleotide biosynthesis as attractive targets for anticancer therapy.

Shuvalov O, Petukhov A, Daks A, Fedorova O, Vasileva E, Barlev NA.

Oncotarget. 2017 Apr 4;8(14):23955-23977. doi: 10.18632/oncotarget.15053. Review.

16.

TUMOR MICROENVIRONMENT REGULATION BY HYPOXIA-INDICIBLE FACTORS (HIFs), AND p53 FAMILY PROTEINS.

Petrova VS, Barlev NA.

Tsitologiia. 2017;59(4):259-70. Review. English, Russian.

PMID:
30188089
17.

BTK Modulates p53 Activity to Enhance Apoptotic and Senescent Responses.

Althubiti M, Rada M, Samuel J, Escorsa JM, Najeeb H, Lee KG, Lam KP, Jones GD, Barlev NA, Macip S.

Cancer Res. 2016 Sep 15;76(18):5405-14. doi: 10.1158/0008-5472.CAN-16-0690. Epub 2016 Jul 26.

18.

Human EHMT2/G9a activates p53 through methylation-independent mechanism.

Rada M, Vasileva E, Lezina L, Marouco D, Antonov AV, Macip S, Melino G, Barlev NA.

Oncogene. 2017 Feb 16;36(7):922-932. doi: 10.1038/onc.2016.258. Epub 2016 Jul 25.

PMID:
27452519
19.

Extracellular Proteasomes Are Deficient in 19S Subunits as Revealed by iTRAQ Quantitative Proteomics.

Tsimokha AS, Zaykova JJ, Bottrill A, Barlev NA.

J Cell Physiol. 2017 Apr;232(4):842-851. doi: 10.1002/jcp.25492. Epub 2016 Aug 16.

PMID:
27430664
20.

Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy.

Clausse V, Goloudina AR, Uyanik B, Kochetkova EY, Richaud S, Fedorova OA, Hammann A, Bardou M, Barlev NA, Garrido C, Demidov ON.

Cell Death Dis. 2016 Apr 14;7:e2195. doi: 10.1038/cddis.2016.96.

Supplemental Content

Loading ...
Support Center